Bertrand Pourroy

1.2k total citations
47 papers, 823 citations indexed

About

Bertrand Pourroy is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bertrand Pourroy has authored 47 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bertrand Pourroy's work include Safe Handling of Antineoplastic Drugs (7 papers), Pharmaceutical studies and practices (7 papers) and Cancer Treatment and Pharmacology (7 papers). Bertrand Pourroy is often cited by papers focused on Safe Handling of Antineoplastic Drugs (7 papers), Pharmaceutical studies and practices (7 papers) and Cancer Treatment and Pharmacology (7 papers). Bertrand Pourroy collaborates with scholars based in France, United States and Zambia. Bertrand Pourroy's co-authors include Diane Braguer, Manon Carré, Claudette Briand, Nicolás André, Eddy Pasquier, Laurence Camoin‐Jau, Hervé Kovacic, Gaël Brasseur, Joseph Ciccolini and Bruno Lacarelle and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Scientific Reports.

In The Last Decade

Bertrand Pourroy

44 papers receiving 809 citations

Peers

Countries citing papers authored by Bertrand Pourroy

Since Specialization

Citations

This map shows the geographic impact of Bertrand Pourroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Pourroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Pourroy more than expected).

Fields of papers citing papers by Bertrand Pourroy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertrand Pourroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Pourroy. The network helps show where Bertrand Pourroy may publish in the future.

Co-authorship network of co-authors of Bertrand Pourroy

This figure shows the co-authorship network connecting the top 25 collaborators of Bertrand Pourroy. A scholar is included among the top collaborators of Bertrand Pourroy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertrand Pourroy. Bertrand Pourroy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigator‐Initiated Clinical Pharmacokinetic Studies in Resource‐Limited Settings: Minimal Requirements and Practical Guidance 2025 ·The Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), Bertrand Pourroy, (unknown), (unknown), Gertjan J.L. Kaspers, Festus Njuguna	1
2	The pharmaceutical circuit of Advanced Therapy Medicinal Products—guidelines of the French Society for Oncology Pharmacy 2025 ·Cytotherapy ·Bertrand Pourroy, Isabelle Madelaine, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Catherine Rioufol, (unknown), Miryam Mebarki	1
3	Oncology pharmacy practice: Key insights, challenges, and perspectives – A position paper from the French Society for Oncology Pharmacy (SFPO) 2025 ·Annales Pharmaceutiques Françaises ·Florence Ranchon, Florian Slimano, Isabelle Borget, (unknown), Christophe Bardin, (unknown), (unknown), (unknown), Raphaëlle Fanciullino, Muriel Paul, Florent Puisset, Catherine Rioufol, (unknown), Jean‐François Tournamille, Jean Vigneron, (unknown), Bertrand Pourroy, (unknown)	0
4	Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated 2024 ·Frontiers in Medicine ·(unknown), (unknown), Sylvain Auvity, Bertrand Pourroy, (unknown), (unknown), (unknown), (unknown)	3
5	European Association of Hospital Pharmacists (EAHP) guidance on the pharmacy handling of in vivo gene therapy medicinal products 2024 ·European Journal of Hospital Pharmacy ·(unknown), Sylvain Auvity, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bertrand Pourroy, Nicola Stoner	3
6	Circuit pharmaceutique du médicament de thérapie innovante (MTI) en France : état des lieux et perspectives 2023 ·Annales Pharmaceutiques Françaises ·(unknown), (unknown), (unknown), Bertrand Pourroy	4
7	Cancer de la vessie localement avancé ou métastatique : identification des freins et leviers du parcours des patients en France 2022 ·Bulletin du Cancer ·Nadine Houédé, Cécile Flahault, Marine Gross‐Goupil, (unknown), (unknown), (unknown), G. Pignot, Bertrand Pourroy, Constance Thibault, Évanguelos Xylinas, (unknown), (unknown), Morgan Rouprêt	0
8	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines) 2020 ·Cancer Treatment Reviews ·Florian Slimano, (unknown), Jérémie Zerbit, (unknown), Audrey Thomas‐Schoemann, (unknown), Mikaël Daouphars, Isabelle Madelaine, Bertrand Pourroy, Jean‐François Tournamille, A. Astier, Florence Ranchon, (unknown), Christophe Bardin, Catherine Rioufol	33
9	Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone 2019 ·European Journal Of Haematology ·(unknown), Geoffroy Venton, (unknown), Pierre Suchon, (unknown), Cédric Mercier, Laure Farnault, (unknown), Marina Lafage, Corinne Brunet, (unknown), Bertrand Pourroy, (unknown), Régis Costello	0
10	Availability of Morphine Oral Solution for Childhood Cancer Patients in Low-Income Countries: Compounding and Stability Study in a Cote d'Ivoire University Teaching Hospital 2019 ·Journal of Pain and Symptom Management ·Bertrand Pourroy, Christophe Curti, Edouard Lamy, (unknown), (unknown), Patrice Vanelle	3
11	Acute myositis 2018 ·Anti-Cancer Drugs ·Philippe Rochigneux, N. Schleinitz, Mikaël Ebbo, (unknown), Bertrand Pourroy, R. Boissier, Sébastien Salas, Jean‐Laurent Deville	13
12	From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer 2018 ·International Journal of Nanomedicine ·Anne Rodallec, (unknown), Sarah Giacometti, Manon Carré, Bertrand Pourroy, Fanny Bouquet, Ariel Savina, Bruno Lacarelle, Joseph Ciccolini, Raphaëlle Fanciullino	26
13	Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization 2015 ·International Journal of Pharmaceutics ·Youssef Bennis, (unknown), Florian Corréard, Marc Montana, (unknown), (unknown), P. Pisano, Bertrand Pourroy	3
14	Pertinence des prescriptions « hors AMM/RTU » des molécules onéreuses dans un hôpital universitaire 2015 ·Therapies ·(unknown), (unknown), Bertrand Pourroy, (unknown), P. Pisano, Pascal Rathelot, B. Vialettes	2
15	Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? 2014 ·International Journal of Clinical Pharmacy ·Youssef Bennis, (unknown), (unknown), (unknown), P. Pisano, Bertrand Pourroy	26
16	Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma 2006 ·Anti-Cancer Drugs ·(unknown), Bertrand Pourroy, Angélique Rome, (unknown), Carole Coze, G. Gorincour, Corinne Bouvier, Diane Braguer, Nicolás André	6
17	Therapeutic Drug Monitoring for Dose Individualization of Cisplatin in Testicular Cancer Patients Based Upon Total Platinum Measurement in Plasma 2006 ·Therapeutic Drug Monitoring ·Sébastien Salas, Cédric Mercier, Joseph Ciccolini, Bertrand Pourroy, Raphaëlle Fanciullino, Brigitte Tranchand, Suzanne Monjanel‐Mouterde, (unknown), Charlotte Dupuis, Chenguang Yang, (unknown), Bruno Lacarelle, (unknown), (unknown), Roger Favre	33
18	Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine 2006 ·Anti-Cancer Drugs ·(unknown), Véronique Bourgarel‐Rey, (unknown), Bertrand Pourroy, Diego Arango, Diane Braguer, Yves Barra	22
19	Neurotoxicité de l’oxaliplatine : trois cas d’exacerbation post-opératoire 2005 ·Gastroentérologie Clinique et Biologique ·(unknown), Pauline Ries, (unknown), (unknown), Laëtitia Dahan, Philippe Grandval, Bertrand Pourroy, Vincent Moutardier, Jean Hardwigsen, (unknown), Jean‐François Seitz	4
20	Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells 2002 ·FEBS Letters ·Nicolás André, Manon Carré, Gaël Brasseur, Bertrand Pourroy, Hervé Kovacic, Claudette Briand, Diane Braguer	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact